Title: | Pharmacodynamics and Medicinal Chemistry of an External Chinese Herbal Formula for Mammary Precancerous Lesions |
Author(s): | Chen R; Zhang G; Ma Y; Bie F; Fan H; Ma M; |
Address: | "School of Chinese Medicine, Jinan University, Guangzhou, Guangdong 510632, China. The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong 510630, China. Institute of Biomedicine, Department of Cellular Biology, Guangdong Province Key Lab of Bioengineering Medicine, Jinan University, Guangzhou, Guangdong 510632, China. College of Pharmacy, Jinan University, Guangzhou, Guangdong 510632, China" |
Journal Title: | Evid Based Complement Alternat Med |
ISSN/ISBN: | 1741-427X (Print) 1741-4288 (Electronic) 1741-427X (Linking) |
Abstract: | "Ruyan Neixiao Cream (RYNXC) is a traditional Chinese herbal formula for treating mammary precancerous disease. This study was carried out to investigate in vivo anticancer effect of RYNXC and multiple constituents. 32 virginal Sprague-Dawley rats were randomly divided into blank control group (BC), mammary precancer models group (MODEL), tamoxifen group (TAM), and Ruyan Neixiao Cream group (RYNXC). TAM was intervened by tamoxifen; RYNXC was intervened by Ruyan Neixiao Cream. The chromatographic separation was performed by high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS). RYNXC showed significant improvement in erythrocyte aggregation index (EAI), hematocrit (HCT), fibrinogen (FIB), spleen coefficient, and uterus coefficient compared with MODEL. In RYNXC and TAM groups, atypical hyperplasia was observed in pathological mammary tissues; meanwhile in MODEL group, ductal carcinoma was observed in situ. Moreover, fifteen compounds were characterized according to HPLC-MS data, including organic acids, tannin, alkaloid, volatile oil, anthraquinones, and flavonoids. The study suggests that RYNXC was an effective Chinese herbal formula for mammary precancerous lesions and provides a scientific basis for the quality standard and the pharmacology of RYNXC. It will be beneficial to the future clinical application of RYNXC" |
Notes: | "PubMed-not-MEDLINEChen, Ruixue Zhang, Guijuan Ma, Yi Bie, Fengjie Fan, Hongxia Ma, Min eng 2017/08/16 Evid Based Complement Alternat Med. 2017; 2017:6235027. doi: 10.1155/2017/6235027. Epub 2017 Jul 24" |